These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23507208)

  • 1. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review.
    Bitton A; Choudhry NK; Matlin OS; Swanton K; Shrank WH
    Am J Med; 2013 Apr; 126(4):357.e7-357.e27. PubMed ID: 23507208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Secondary Prevention (MISSION-1) Study.
    Rao C; Du J; Li X; Li J; Zhang H; Zhao Y; Hu S; Jiang L; Zheng Z;
    Am Heart J; 2016 Aug; 178():9-18. PubMed ID: 27502847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonadherence to Statins and Antihypertensives and Hospitalizations Among Elderly Medicare Beneficiaries With Incident Cancer.
    Chopra I; Dwibedi N; Mattes MD; Tan X; Findley P; Sambamoorthi U
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1351-1360. PubMed ID: 29118227
    [No Abstract]   [Full Text] [Related]  

  • 4. Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
    Griffiths B; Lesosky M; Ntsekhe M
    S Afr Med J; 2014 Jun; 104(7):483-7. PubMed ID: 25214049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing prevention and guideline-concordant care in Montenegro.
    Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
    Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.
    Kumbhani DJ; Steg PG; Cannon CP; Eagle KA; Smith SC; Hoffman E; Goto S; Ohman EM; Bhatt DL;
    Am J Med; 2013 Aug; 126(8):693-700.e1. PubMed ID: 23800583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous coronary intervention vs. optimal medical therapy--the other side of the coin: medication adherence.
    Kocas C; Abaci O; Oktay V; Coskun U; Bostan C; Yildiz A; Arat Ozkan A; Gurmen T; Ersanli M
    J Clin Pharm Ther; 2013 Dec; 38(6):476-9. PubMed ID: 23992279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with coronary artery disease after acute myocardial infarction: effects of continuous enrollment in a structured Disease Management Program on adherence to guideline-recommended medication, health care expenditures, and survival.
    Kirsch F; Becker C; Schramm A; Maier W; Leidl R
    Eur J Health Econ; 2020 Jun; 21(4):607-619. PubMed ID: 32006188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease.
    Ladapo JA; Hoffmann U; Lee KL; Coles A; Huang M; Mark DB; Dolor RJ; Pelberg RA; Budoff M; Sigurdsson G; Severance HW; Douglas PS
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27733347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
    Naderi SH; Bestwick JP; Wald DS
    Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Length of initial prescription at hospital discharge and long-term medication adherence for elderly patients with coronary artery disease: a population-level study.
    Ivers NM; Schwalm JD; Jackevicius CA; Guo H; Tu JV; Natarajan M
    Can J Cardiol; 2013 Nov; 29(11):1408-14. PubMed ID: 23816280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
    Gencer B; Rodondi N; Auer R; Räber L; Klingenberg R; Nanchen D; Carballo D; Vogt P; Carballo S; Meyer P; Matter CM; Windecker S; Lüscher TF; Mach F
    Eur J Intern Med; 2015 Jan; 26(1):56-62. PubMed ID: 25582072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Socioeconomic Factors, Secondary Prevention Medication, and Long-Term Survival After Coronary Artery Bypass Grafting: A Population-Based Cohort Study From the SWEDEHEART Registry.
    Nielsen SJ; Karlsson M; Björklund E; Martinsson A; Hansson EC; Malm CJ; Pivodic A; Jeppsson A
    J Am Heart Assoc; 2020 Mar; 9(5):e015491. PubMed ID: 32114890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Secondary Prevention Medication on the Prognosis in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
    Abdu FA; Liu L; Mohammed AQ; Xu B; Yin G; Xu S; Xu Y; Che W
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):678-683. PubMed ID: 33284169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions supporting long term adherence and decreasing cardiovascular events after myocardial infarction (ISLAND): pragmatic randomised controlled trial.
    Ivers NM; Schwalm JD; Bouck Z; McCready T; Taljaard M; Grace SL; Cunningham J; Bosiak B; Presseau J; Witteman HO; Suskin N; Wijeysundera HC; Atzema C; Bhatia RS; Natarajan M; Grimshaw JM
    BMJ; 2020 Jun; 369():m1731. PubMed ID: 32522811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
    Pitts R; Daugherty SL; Tang F; Jones P; Ho PM; Tsai TT; Spertus J; Maddox TM
    Clin Cardiol; 2017 Jun; 40(6):347-355. PubMed ID: 28387960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary prevention of coronary heart disease? What is cost effective in the clinical practice?].
    Kübler W
    Z Kardiol; 2005; 94 Suppl 3():III/92-9. PubMed ID: 16258799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The COACH program produces sustained improvements in cardiovascular risk factors and adherence to recommended medications-two years follow-up.
    Jelinek M; Vale MJ; Liew D; Grigg L; Dart A; Hare DL; Best JD
    Heart Lung Circ; 2009 Dec; 18(6):388-92. PubMed ID: 19648058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term adherence with cardiovascular drug regimens.
    Kulkarni SP; Alexander KP; Lytle B; Heiss G; Peterson ED
    Am Heart J; 2006 Jan; 151(1):185-91. PubMed ID: 16368315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.